This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Breast cancer	γ -aminobutyric acid A receptor- π (GABRP)	<i>In vitro</i> studies suggest inhibiting GABRP could help treat and prevent metastasis of basal-like breast cancers. In samples from patients with basal-like breast cancer, GABRP expression was greater than that in samples from other cancer subtypes, and high levels of expression associated with poor overall survival within the subset. In two aggressive human basal-like breast cancer cell lines, an shRNA targeting <i>GABRP</i> decreased <i>in vitro</i> tumorsphere formation and cell migration compared with a control shRNA. Next steps include conducting <i>in vivo</i> studies of GABRP function in brain metastases and developing a GABRP inhibitor.	Unpatented; licensing status not applicable	Sizemore, G.M. <i>et al. J. Biol. Chem.</i> ; published online July 10, 2014; doi:10.1074/jbc.M114.593582 Contact: Ruth A. Keri, Case Western Reserve University, Cleveland, Ohio e-mail: keri@case.edu
SciBX 7(33); doi:10.1038/scibx.2014.977 Published online Aug. 28, 2014				